SecBot SecBot
6-K ·Filed Nov 12, 2026

PHVS

Pharvaris N.V.
NEUTRAL
Impact 4/10
Horizonmonths Processed4d 20h ago SEC0001193125-26-456847
6-K: Earnings release
Actionable Insight • Neutral

The PDUFA date of April 23, 2027 for deucrictibant IR is the primary near-term catalyst. Monitor for any FDA advisory committee meeting announcements and the CREAATE topline data expected in Q1 2027. The company's cash runway appears adequate through the PDUFA date, but the increasing operating burn rate warrants attention.

DirectionNeutral
Confidencemedium
Horizonmonths

deucrictibant

◆ Mixed Named in this 6-K
Impact
Phase
Filed/PDUFA (IR capsule); Phase 3 (XR tablet)
Time to market
IR capsule could be approved by April 23, 2027 PDUFA date. XR tablet for prophylaxis would follow later, likely 2028+ if CHAPTER-3 is positive.
Next catalyst
None dated

What to watchTwo binary catalysts in the next ~9 months: CHAPTER-3 topline (Q3 2026) and the PDUFA decision on the IR capsule (April 23, 2027). The bigger swing factor near-term is CHAPTER-3, a positive readout would validate the larger prophylactic market opportunity, while a miss would severely dent the thesis given that sebetralstat (KalVista) already beat deucrictibant to market as the first oral on-demand HAE therapy.

Price Chart

Loading chart...

Executive Summary

Pharvaris reported Q3 2026 results showing a net loss of EUR 47.4M ($0.67 per share), wider than the EUR 37.1M loss in Q3 2025, driven by a 79% increase in G&A expenses as the company builds commercial infrastructure ahead of a potential 2027 launch. The key stock-moving event is the ongoing FDA review of deucrictibant IR with a PDUFA date of April 23, 2027, and the successful CHAPTER-3 Phase 3 readout for deucrictibant XR prophylaxis, with an NDA submission planned for 1H2027. Cash position remains strong at EUR 283M, sufficient to fund operations for at least 12 months.

Key Financial Metrics

EPS
−$0.67
Revenue
$0.00
est $0.00
Free Cash Flow
-$128.9M

Key Facts

  • Q3 2026 net loss of EUR 47.4M ($0.67 per share) vs EUR 37.1M ($0.60) in Q3 2025
  • R&D expenses EUR 32.4M, up 9% YoY; G&A expenses EUR 17.7M, up 79% YoY
  • Cash and cash equivalents EUR 283M as of September 30, 2026
  • Deucrictibant IR NDA under FDA review with PDUFA date of April 23, 2027
  • CHAPTER-3 Phase 3 study met primary and all secondary endpoints; NDA for XR prophylaxis planned 1H2027
  • Topline data from CREAATE Phase 3 study in AAE-C1INH expected in Q1 2027
  • No revenue generated; pre-revenue biopharmaceutical company

Financial Impact

Net loss widened by EUR 10.3M YoY in Q3; operating cash burn EUR 128.8M in 9M 2026

net lossoperating expensescash burn

Risk Factors

  • FDA may not approve deucrictibant IR by the PDUFA date or at all
  • Increasing operating expenses and cash burn rate as commercial build-out accelerates
  • Clinical trial risks for CREAATE and XR programs
  • No revenue until potential approval and launch, expected in 2027 at the earliest
  • Dependence on additional financing for operations beyond 12 months

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-456847
Document: phvs-ex99_2.htm0001193125-26-456847
Document: phvs-ex99_1.htm0001193125-26-456847
Document: 6-k_q3_26.htm0001193125-26-456847
Document: 0001193125-26-456847-index-headers.html0001193125-26-456847
Document: 0001193125-26-456847-index.html0001193125-26-456847
Document: 0001193125-26-456847.txt0001193125-26-456847
Earnings Context (Synthetic; results releases only)0001193125-26-456847

Track record

51 reports on PHVS

Performance horizon

15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  4. Nov 12, 20264d ago 6-K Neutral 4/10 Viewing No price data
  5. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  6. Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
  7. Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  8. Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  9. Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
  10. Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
Showing 10 of 51

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026